Clinical Trial Update: Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating exemestane with or without entinostat (SNDX-275) in postmenopausal women with advanced estrogen receptor-positive breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• SNDX-275 (entinostat)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-24